Robert I Blum, Director, President & CEO, on July 13, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $615,150. Following the Form 4 filing with the SEC, Blum has control over a total of 381,986 common shares of the company, with 377,820 shares held directly and 4,166 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1061983/000106198326000077/xslF345X05/form4.xml
Price: $81.68, Change: $-0.56, Percent Change: -0.68%
Juan C. Jaen, President, on July 09, 2026, sold 68,569 shares in Arcus Biosciences (RCUS) for $2,031,919. Following the Form 4 filing with the SEC, Jaen has control over a total of 1,200,531 common shares of the company, with 378,291 shares held directly and 822,240 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1724521/000142299626000006/xslF345X05/wk-form4_1783978603.xml
Susan J.S. Taylor, Director, on July 09, 2026, sold 8,543 shares in Everpure (P) for $698,305. Following the Form 4 filing with the SEC, Taylor has control over a total of 94,608 Class A common shares of the company, with 94,608 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1474432/000147443226000078/xslF345X05/wk-form4_1783978249.xml
Charles H Giancarlo, Director, CEO, on July 09, 2026, sold 135,800 shares in Everpure (P) for $10,915,063. Following the Form 4 filing with the SEC, Giancarlo has control over a total of 2,411,011 Class A common shares of the company, with 1,679,597 shares held directly and 731,414 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1474432/000129963426000017/xslF345X05/wk-form4_1783978410.xml